{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T18:55:33Z","timestamp":1766516133400},"reference-count":10,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2007,3,2]],"date-time":"2007-03-02T00:00:00Z","timestamp":1172793600000},"content-version":"vor","delay-in-days":6634,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[1989,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Seventeen unselected patients with relapsed or refractory multiple myeloma were treated with oral prednisolone 60 mg per m<jats:sup>2<\/jats:sup> for five consecutive days with nine\u2010day treatment\u2010free intervals. Of the fourteen patients who completed at least six courses of treatment there were five good responses (Chronic Leukemia\u2013Myeloma Task Force Criteria), five partial responses and four failures. Median survival (all seventeen patients) was between 19 and 20 months. Eight patients achieved plateau phase (median duration 9 months). Eleven patients showed improved performance status and four became free of transfusion support. The commonest side\u2010effect was bacterial pulmonary infection. Peptic ulceration occurred in two patients despite prophylactic ranitidine. Other steroid\u2010related side\u2010effects were mild and well tolerated. This study provides further evidence for the efficacy of higher dose steroid regimens in relapsed or refractory myelomatosis and confirms that durable remissions may be achieved. Responders show a gratifying improvement in quality of life and are spared the many toxicities of combination cytotoxic chemotherapy. Further studies of high dose steroid regimens in first\u2010line therapy, especially in patients with bone marrow suppression, are clearly merited.<\/jats:p>","DOI":"10.1002\/hon.2900070107","type":"journal-article","created":{"date-parts":[[2007,2,19]],"date-time":"2007-02-19T20:08:22Z","timestamp":1171915702000},"page":"61-68","source":"Crossref","is-referenced-by-count":6,"title":["Pulsed high dose oral prednisolone in relapsed or refractory multiple myeloma"],"prefix":"10.1002","volume":"7","author":[{"given":"D. R.","family":"Norfolk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Child","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,3,2]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood.V62.3.572.572","article-title":"Prednisone pulse therapy for refractory myeloma","volume":"62","author":"Alexanian R.","year":"1983","journal-title":"Blood"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-105-1-8"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198405243102104"},{"key":"e_1_2_1_5_1","first-page":"145","article-title":"Proposed guidelines for protocol studies II. Plasma cell myeloma","volume":"4","author":"Chronic Leukaemia\u2013Myeloma Task Force","year":"1973","journal-title":"Cancer Chemother. Rep."},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4731(86)90426-7"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2964(81)90040-2"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198405243102109"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950130502"},{"key":"e_1_2_1_11_1","first-page":"179","article-title":"Intermittent high dose prednisone therapy for multiple myeloma","volume":"51","author":"Salmon S. E.","year":"1967","journal-title":"Cancer Chemother. Rep."}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2900070107","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2900070107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T01:16:26Z","timestamp":1697937386000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2900070107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1989,1]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1989,1]]}},"alternative-id":["10.1002\/hon.2900070107"],"URL":"https:\/\/doi.org\/10.1002\/hon.2900070107","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[1989,1]]}}}